Today (4 May 2021) the MHRA announced the appointment of Dr
Alison Cave as its new Chief Safety Officer. As a member of the
Executive Committee, Alison will lead on safety and vigilance
functions and become a Board Director of the Agency.
Alison is a pharmacologist with a PhD in biochemistry. Her long
career includes significant academic and regulatory experience,
the latter initially at the Medicines Control Agency and then in
senior roles within the Vigilance and Risk Management of Medicine
Group at the MHRA and the European Medicines Agency (EMA). Most
recently she was an Industrial Strategy Challenge Fund Director
at UK Research and Innovation.
We are delighted to welcome Dr Alison Cave to the team. This is
a key appointment for the agency which signals our commitment
to ensuring patient voice is at the heart of everything we do.
Alison’s wealth of academic knowledge, experience of working in
partnership with industry and regulatory expertise will inform
and strengthen our safety and vigilance functions and makes her
the ideal champion for the patient voice.
I am tremendously excited to be joining the MHRA as Chief
Safety Officer at a time when a rapidly changing scientific,
technological and analytical landscape is bringing us new
opportunities to evolve the evidence generation around the
benefits and risks of medicines and devices.
I look forward to working with colleagues at MHRA to continue
to improve our medicines and devices safety surveillance in the
UK and in facilitating the close partnerships with patients and
healthcare professionals envisaged by the Cumberlege report.
Alison will take up her post on 19 July 2021.
